Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Despite the known benefits of geriatric care models among hospitalized older adults outside the intensive care unit (ICU), few studies have addressed the needs of older adults in the ICU; for example, sensory impairment, functional decline, and deprescribing of potentially inappropriate medications (PIMs) are rarely addressed in routine ICU practice. This pilot study will evaluate the feasibility, acceptability, and barriers to implementation of a geriatrics bundle (occupational therapy, assessment and treatment of hearing impairment, and deprescribing PIMs) in the ICU.
Description: Feasibility of bundle delivery will be measured by review of electronic medical record (EMR) documentation of each bundle component and a daily-check in with the patient and team. We will determine the proportion of eligible patients receiving each component as well as delivery of the overall bundle. A feasibility threshold of 70% will be used for the individual bundle components, as well as the combined bundle.
Measure: Feasibility of bundle delivery Time: From ICU admission to hospital discharge, up to 30 daysDescription: Acceptability of the bundle among providers delivering the interventions will be assessed with a survey using a 10-point Likert scale (range 1-10, where 10 indicates that the bundle is completely acceptable for use in its current form).
Measure: Acceptability of bundle delivery Time: From ICU admission to hospital discharge, up to 30 daysDescription: Barriers and facilitators to bundle implementation will be assessed using qualitative methods.
Measure: Barriers (and facilitators) to bundle implementation Time: From ICU admission to hospital discharge, up to 30 daysDescription: Incident delirium and days of delirium will be determined by review of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) charting in the electronic medical record.
Measure: Delirium Time: From ICU admission to hospital discharge, up to 30 daysDescription: Data about mobility level during hospitalization will be gathered from the physical therapy and occupational therapy flowsheets.
Measure: Mobility level Time: From ICU admission to hospital discharge, up to 30 daysDescription: Manual muscle testing via the 6-point MRC system: Strength in each of 12 muscle groups is assessed via a 6-point system, in which a score of 0=no contraction, 1=flicker of a contraction, 2=active movement with gravity eliminated, 3=active movement against gravity, 4=active movement against gravity and resistance, 5= normal power.
Measure: Muscle strength Time: From ICU admission to hospital discharge, up to 30 daysDescription: Participants will be asked whether they were independently able to complete a series of functional activities, including activities of daily living (ADLs), instrumental activities of daily living (IADLs), and mobility activity.
Measure: 30-day functional outcomes Time: 30 days after hospital dischargeDescription: Hospital readmissions, emergency department visits, and other illnesses/injuries
Measure: 30-day health outcomes Time: 30 days after hospital dischargeDescription: Participants will be asked whether they are still using the portable amplifying device after hospital discharge and whether they perceive benefit from its use.
Measure: Use and perceived benefit of amplifying device after hospital discharge Time: 30 days after hospital dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports